skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Find Out More

State of the Industry 2019:

KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables.

The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.

Who completed the survey?

214 clinical trials professionals from within pharma and biotech (28%), CROs (29%), service providers, consultancies and medical device companies (26%), investigator sites (6%) and academia (4%) responded to the survey. The majority of respondents were from Europe (66%) followed by North America (17%) and Asia (13%).

Citeline_CLINICAL_TRIALS_RESEARCH_REPORT_cover

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pipeline-In-A-Pill: Still A Winning Strategy?

    By Daniel Chancellor

    “Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

    Topics BioPharmaceutical Drug Pricing Drug Review Drug Development Landscape

  • Citeline, In Vivo: strategic insights for life sciences deci...

    Pharma R&D’s COVID-19 Scar

    By Duncan Emerton

    Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

    Topics Coronavirus Research & Development

  • Citeline

    Clinical Trials 2019 Round-up

    The clinical trial landscape continues to evolve as scientific breakthroughs and technological innovations emerge. Examine the state of Phase I–III clinical trials initiated in 2019 when you download the Annual Clinical Trials Roundup from Citeline’s Trialtrove, your trusted source for global clinical trials intelligence.

    Topics Clinical Trials

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: